Recent Investment Analysts’ Ratings Changes for Denali Therapeutics (DNLI)

Several brokerages have updated their recommendations and price targets on shares of Denali Therapeutics (NASDAQ: DNLI) in the last few weeks:

• 1/15/2025 – Denali Therapeutics had its “outperform” rating reaffirmed by analysts at William Blair.
• 1/7/2025 – Denali Therapeutics was upgraded by analysts at Baird R W to a “strong-buy” rating.
• 1/7/2025 – Denali Therapeutics had its price target lowered by analysts at JPMorgan Chase & Co. from $28.00 to $24.00. They now have an “overweight” rating on the stock.
• 1/7/2025 – Denali Therapeutics is now covered by analysts at Robert W. Baird. They set an “outperform” rating and a $31.00 price target on the stock.
• 1/7/2025 – Denali Therapeutics had its price target lowered by analysts at HC Wainwright from $90.00 to $87.00. They now have a “buy” rating on the stock.
• 1/3/2025 – Denali Therapeutics is now covered by analysts at William Blair. They set an “outperform” rating on the stock.
• 12/16/2024 – Denali Therapeutics was upgraded by analysts at Stifel Nicolaus from a “hold” rating to a “buy” rating. They now have a $37.00 price target on the stock.

Denali Therapeutics Stock Performance

NASDAQ DNLI traded up $0.17 on Thursday, hitting $21.67. 1,290,753 shares of the stock traded hands, compared to its average volume of 1,143,232. The business’s fifty day moving average is $23.48 and its two-hundred day moving average is $24.77. The firm has a market capitalization of $3.12 billion, a price-to-earnings ratio of -7.85 and a beta of 1.39. Denali Therapeutics Inc. has a 12 month low of $14.56 and a 12 month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI) last posted its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.60) by ($0.03). During the same period in the previous year, the firm posted ($0.72) earnings per share. Analysts expect that Denali Therapeutics Inc. will post -2.73 EPS for the current fiscal year.

Insider Buying and Selling at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,020 shares of the company’s stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $30.00, for a total value of $30,600.00. Following the transaction, the director now owns 111,056 shares of the company’s stock, valued at approximately $3,331,680. This represents a 0.91 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Alexander O. Schuth sold 15,558 shares of Denali Therapeutics stock in a transaction on Thursday, November 7th. The shares were sold at an average price of $29.91, for a total value of $465,339.78. Following the sale, the insider now directly owns 178,066 shares of the company’s stock, valued at $5,325,954.06. This represents a 8.04 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 104,518 shares of company stock valued at $2,576,982 in the last quarter. 7.90% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Denali Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. MONECO Advisors LLC grew its stake in Denali Therapeutics by 4.6% in the 3rd quarter. MONECO Advisors LLC now owns 9,100 shares of the company’s stock worth $265,000 after buying an additional 400 shares in the last quarter. Assetmark Inc. increased its stake in Denali Therapeutics by 18.0% in the third quarter. Assetmark Inc. now owns 3,808 shares of the company’s stock valued at $111,000 after acquiring an additional 580 shares during the last quarter. CWM LLC raised its position in Denali Therapeutics by 43.6% during the third quarter. CWM LLC now owns 2,153 shares of the company’s stock valued at $63,000 after purchasing an additional 654 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in Denali Therapeutics by 21.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,178 shares of the company’s stock worth $152,000 after purchasing an additional 920 shares during the last quarter. Finally, Quest Partners LLC bought a new stake in Denali Therapeutics during the third quarter worth about $73,000. 92.92% of the stock is owned by hedge funds and other institutional investors.

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.